Mon, 26 Aug 2019 13:46:31 GMT
Amgen to acquire Celgene's Otezla in $13.4B cash-deal
On Monday, Amgen Inc stated it would acquire Celgene's psoriasis drug Otezla in a cash-deal worth $13.4B, paving the way for the American pharmaceutical company Bristol-Myers Squibb to bid for Celgene with the $74B worth offer.